Good news is always welcome, but unexpected good news in the fight against COVID-19 is even sweeter. During this past year as COVID-19 held the United States and the rest of the world hostage, good news has been scarce and usually centered around the development, rollout and distribution of vaccines — but even this bright spot has been exceedingly frustrating.

The unexpected good news delivered by President Joe Biden was the historic partnership between pharmaceutical companies Merck and Johnson & Johnson to manufacture the latter’s COVID-19 vaccine. This will help make it possible to have enough shots for every adult in the country by the end of May. The Biden administration previously set this goal for the end of July.

Recommended for you

(0) comments

Welcome to the discussion.

Keep the discussion civilized. Absolutely NO personal attacks or insults directed toward writers, nor others who make comments.
Keep it clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't threaten. Threats of harming another person will not be tolerated.
Be truthful. Don't knowingly lie about anyone or anything.
Be proactive. Use the 'Report' link on each comment to let us know of abusive posts.
PLEASE TURN OFF YOUR CAPS LOCK.
Anyone violating these rules will be issued a warning. After the warning, comment privileges can be revoked.

Thank you for visiting the Daily Journal.

Please purchase a Premium Subscription to continue reading. To continue, please log in, or sign up for a new account.

We offer one free story view per month. If you register for an account, you will get two additional story views. After those three total views, we ask that you support us with a subscription.

A subscription to our digital content is so much more than just access to our valuable content. It means you’re helping to support a local community institution that has, from its very start, supported the betterment of our society. Thank you very much!

Want to join the discussion?

Only subscribers can view and post comments on articles.

Already a subscriber? Login Here